Analytical Data
-
Gene name
Slc17a6
- Application
-
Alternative Names
(VGluT2)(Differentiation-associated BNPI)(Differentiation-associated Na(+)(Solute carrier family 17 member 6)
-
Species
Rat
-
Source
Yeast
-
Tag
C- His
-
Purity
Greater than 90% as determined by SDS-PAGE.
-
Uniprot
Q9JI12
-
Expression Region
499-582aa
-
Molecular Weight
11.1 kDa
-
Endotoxin
< 1.0 EU per μg protein as determined by the LAL method.
-
Form
Freeze-dried powder
-
Buffer formulation
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
Reconstitution
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- Customization
-
Stability Test
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
Storage & Shelf Life
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
Shipping
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
Quality inspection process
Related Products
Protein Description
The study of the Slc17a6 gene, also known as VGLUT2 (vesicular glutamate transporter 2), is crucial in understanding neurotransmission in the brain. This protein plays a significant role in the packaging of glutamate, the primary excitatory neurotransmitter, into synaptic vesicles, thus influencing synaptic signaling and plasticity. Dysregulation of Slc17a6 expression has been implicated in various neurological disorders, including epilepsy, schizophrenia, and depression. Researchers have sought to produce recombinant Slc17a6 protein to elucidate its structure and function at a molecular level. This recombinant protein enables a variety of biochemical assays and functional studies, providing insights into the transport mechanism and regulatory factors affecting glutamate signaling. Additionally, studying this protein can aid in identifying potential therapeutic targets for treating glutamate-related pathologies. Understanding the intricacies of Slc17a6's operation and its interaction with other proteins within the neural environment could pave the way for advances in neuropharmacology and ultimately improve treatment strategies for neuronal diseases.
